205results about "Transforming growth factor" patented technology

To provide induced regulatory T cells with high function and stable immunosuppressive function.SOLUTION: The present invention provides an induced human regulatory T cell having at least one characteristic selected from the group consisting of FoxP3-positive, CTLA4-positive, NT5E-positive, ITGAE (CD103)-positive, AREG-positive, CD172 g-positive, and CD26-positive, which is induced by obtaining stable inducible T cells induced from human peripheral T cells by stimulation with an anti-CD3 antibody when regulatory T cells are induced from human peripheral T cells, subsequently subjecting the cells to resting culture, stimulating the cells with anti-CD3 antibody again to culture them, and further subjecting the cells to resting culture.SELECTED DRAWING: None

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Fusion molecules comprising an obesity-related peptide moiety, fused to a myostatin pathway inhibitor moiety are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods of using, the fusion molecules.

The present disclosure provides a polypeptide complex comprising a target binding polypeptide that binds to a molecule on a target cell or a molecule in an extracellular matrix (ECM); and small latent complexes comprising in particular a dimer latent related polypeptide (LAP) or a fragment or derivative thereof, and a dimer mature transforming growth factor beta (TGF beta) family polypeptide or a fragment or derivative thereof. Polypeptides (e.g., fusion polypeptides), and related polynucleotides, vectors, cells, and pharmaceutical compositions are also provided. Also provided are methods of treating subjects using, for example, these polypeptide complexes and / or these fusion polypeptides or pharmaceutical compositions thereof.

The invention relates to proteins for use in the prevention, treatment or amelioration of kidney diseases or kidney damage, more particularly where the protein is a follistatin-fusion protein.

Oncolytic viruses encoding recombinant TGF-β engineered to prevent homodimerization and recruitment of TGF-β receptor I are described. The engineered TGF-β minimonomer functions as a dominant-negative TGF-β inhibitor. Oncolytic viruses encoding TGF-β minimonomers can be used for cancer immunotherapy to inhibit the immunosuppressive tumor microenvironment. Provided are oncolytic viruses encoding recombinant TGF-β monomers, such as human recombinant TGF-β monomers.

Provided herein are codon-optimized Smad7 polynucleotides and vectors comprising codon-optimized Smad7 polynucleotides for use in increasing or prolonging Smad7 expression in a subject.

The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.

Provided herein are macromolecules that conditionally induce a cellular effector function (e.g., a biological or therapeutic activity) based on the presence of a disease signature ligand, compositions comprising the same, and methods of using the same.

Provided herein are methods for generating a protein product, comprising: providing a plant seed; contacting said plant seed with a protein expression vector that encodes for a protein; transiently expressing said protein in said plant seed using said protein expression vector, and isolating said protein from said plant seed to obtain a protein product.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

Disclosed herein are a means to prevent and / or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.

The present invention relates to a pretreatment method for separating and purifying TGF-β3 protein from Escherichia coli with high efficiency and high purity, and a method for purifying TGF-β3 protein including the same. When using the pretreatment method of the present invention and the purification method including the same, since E. coli is used, the process is simpler and higher productivity is expected compared to animal cell culture methods, and therefore highly pure TGF-β3 protein can be separated and purified from E. coli with high efficiency.

Recombinant TGF-β2 monomers engineered to prevent dimerization and block TGF-β signaling are described. The engineered monomers lack the ability to bind and recruit TGF-β type I receptor (TbRI), but retain the capacity to bind the high affinity TGF-β type II receptor (TbRII). The TGF-β2 monomers also include additional modifications that increase their affinity for TbRII, reduce their aggregation and / or improve their folding. Nucleic acid molecules and vectors encoding the recombinant TGF-β2 monomers are also described. Isolated cells, such as T cells, can be re-programmed with a TGF-β2 monomer-encoding nucleic acid or vector to secrete the monomer. Use of the recombinant TGF-β2 monomers and / or cells producing the recombinant TGF-β2 monomers, to inhibit TGF-β signaling, such as to treat disorders associated with aberrant TGF-β signaling, are also described.

The present invention relates to novel naturally occurring and synthetic active peptides or peptide-derived agents designed for the cosmetic treatment of human skin, as well as cosmetic formulations and compositions containing them. The active agents are effective in restoring, promoting, and maintaining healthy skin. In particular, the present invention discloses a combination or set of skin active agents, including stem cell factors, that modulate the skin microenvironment and regulate skin stem cell behavior, thereby effectively healing, regenerating, and improving the condition of aged or damaged skin.

The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration.

The invention provides a regulatory T cell with improved phenotype and functional stability and a preparation method and application thereof. The regulatory T cell disclosed by the invention is co-expressed by membrane protein GARP and TGF-beta, and specifically, the TGF-beta comprises a C33S point mutation precursor TGF-beta 1; further, the regulatory T cell co-expresses a cytokine and a sorting marker, specifically, the cytokine comprises IL-10, and the sorting marker comprises a truncated nerve growth factor receptor tNGFR. The regulatory T cell has more stable phenotype and function stability in in-vivo and in-vitro environments, has important enlightenment value for improving the function stability problem of the regulatory T cell in an inflammatory environment, and has wide application prospects in the fields of treatment of autoimmune diseases, intervention of organ transplantation rejection and the like.

In the field of biological therapy, a major hurdle is the need for a platform technology that enables high bioavailability and long therapeutic exposure of a biological therapy in the setting of localized disease. Classical approaches result in problematic trade-offs such as toxicity and off-target side effects. The present disclosure provides compounds comprising follistatin domain 1 (FSD1) of follistatin (FST) which are able to bind biological structures, such as the extracellular matrix, through heparan sulfates, without bearing the undesirable neutralizing effects on activin A, myostatin, and GDF11 activities of e.g. full-length follistatin. The invention relates to fusion proteins or conjugated proteins, and compositions thereof, constructs or vectors encoding thereof, medical uses thereof and methods for biological therapy.

One of the embodiment of the present invention relates to a fusion protein including a polypeptide represented by Formula (I) and a polypeptide represented by Formula (II) or a dimer thereof. The fusion protein according to the present invention or a dimer thereof is a material with improved in vivo persistence and protein productivity and stability, and has excellent effects of reducing body weight and controlling blood glucose levels.

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac evert as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.

The present invention relates to a composition for treating or preventing neurodevelopmental disorders, particularly autism spectrum disorder, by selectively activating brain-resident regulatory T cells (Tregs). The present composition comprises IL-2 or an IL-2 gene (AAV-GFAP-IL-2) as an active ingredient, and induces Treg proliferation in the brain to alleviate neuroinflammation and improve behavioral defects.

This invention provides a TGFβRII-ECD-based trap with tuned isoform specificity. [Solution] A tetravalent TGFβ receptor-extracellular domain-based trap having a tuned isoform specificity profile for neutralizing TGFβ ligands, and methods for using the same in the treatment of diseases and conditions related to TGFβ, particularly TGFβ1 and TGFβ3, are provided. In particular, a TGFβ conjugate is provided that is designed to tune TGFβ isoform specificity in order to maximize therapeutic effect in specific disease indications while minimizing adverse effects. The TGFβ conjugate comprises two polypeptides assembled via a multimerizing domain, each polypeptide having two TGFβII receptor (TGFβR) ligand-binding domains linked as a doublet, where the linker is selected to tune isoform specificity.

In one aspect, the invention relates to synthetic molecules, compositions and pharmaceutical compositions, which are useful for delivering a bioactive moiety to a site of injury. Also disclosed are methods of treating a tendon injury, methods of treating a fracture, methods of treating a bone stress injury, methods of enhancing incorporation of allograft tissues, methods of promoting repair or regeneration of enthesis tissue during or after an orthopedic surgical procedure, and method of treating osteoporosis, osteoarthritis and / or cartilage defects using the disclosed molecules, compositions and pharmaceutical compositions.

This invention relates to a method for producing extracellular matrix using connective tissue cell culture and to the uses of the produced extracellular matrix. More specifically, it relates to a method for culturing connective tissue cells using a serum-free and heterogeneous culture medium, which can be effectively used to increase the amount of extracellular matrix produced. Furthermore, the extracellular matrix produced by the production method of this invention is derived from human cells and does not contain any heterogeneous components such as fetal bovine serum, making it safe and useful for future development of cell therapy agents, medical supplies, medical devices for tissue treatment, or cosmetic raw materials.

This disclosure provides transforming growth factor β (TGF-β) peptide constructs and complexes that can be used for the therapeutic treatment of diseases, including autoimmune diseases. Nucleic acids encoding the constructs and complexes, as well as methods for preparing the constructs and complexes in a cell-based expression system, are also described.

The present application relates to an animal or cell having a myostatin gene in which 12 base pairs of the second exon are deleted. The present application may also comprise a composition capable of manipulating the deletion of 12 base pairs of a myostatin gene to construct the animal or the cell. The present application also relates to use of the composition for increasing muscle.

The present invention relates to a heavy chain variable domain (V H ) and the light chain variable domain (V L The present invention provides engineered proteins of single-chain variable (scFv) fragments having an albumin-binding portion fused to the single-chain variable fragment, wherein the albumin-binding portion is connected by a linker.

Recombinant TGF-β2 monomers engineered to prevent dimerization and block TGF-β signaling are described. The engineered monomers lack the ability to bind and recruit TGF-β type I receptor (TβRI) but retain the ability to bind high affinity TGF-β type II receptor (TβRII). The TGF-β2 monomers also contain additional modifications that increase their affinity for TβRII, reduce their aggregation, and / or improve their folding. Nucleic acid molecules and vectors encoding recombinant TGF-β2 monomers are also described.